← Back to Screener
Annexon, Inc. Common Stock (ANNX)
Price$5.58
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)11.00%
Price vs S&P 500 (4W)-10.71%
VGM Score68.64
Market Capitalization$888.03M
All Metrics
Book Value / Share (Quarterly)$1.26
P/TBV (Annual)0.63x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.13
Price vs S&P 500 (YTD)-2.97%
EPS (TTM)$-1.20
10-Day Avg Trading Volume2.60M
EPS Excl Extra (TTM)$-1.20
EPS (Annual)$-1.33
ROI (Annual)-97.66%
Cash / Share (Quarterly)$1.38
ROA (Last FY)-74.46%
EBITD / Share (TTM)$-1.22
ROE (5Y Avg)-63.20%
Cash Flow / Share (Annual)$-1.25
P/B Ratio4.34x
P/B Ratio (Quarterly)4.35x
Net Income / Employee (Annual)$-2,153,000
ROA (TTM)-75.99%
EPS Incl Extra (Annual)$-1.33
Current Ratio (Annual)5.68x
Quick Ratio (Quarterly)6.26x
3-Month Avg Trading Volume2.49M
52-Week Price Return148.62%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.95
52-Week High$7.18
EPS Excl Extra (Annual)$-1.33
CapEx CAGR (5Y)-21.51%
Tangible BV CAGR (5Y)142.45%
26-Week Price Return26.93%
Quick Ratio (Annual)5.59x
13-Week Price Return0.74%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.35x
Enterprise Value$712.82M
Book Value / Share Growth (5Y)-30.92%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.60
3-Month Return Std Dev66.59%
Net Income / Employee (TTM)$-2,046,600
ROE (Last FY)-97.66%
EPS Basic Excl Extra (Annual)$-1.33
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.20
ROI (TTM)-101.19%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.84
Price vs S&P 500 (52W)120.42%
Year-to-Date Return7.97%
5-Day Price Return2.07%
EPS Normalized (Annual)$-1.33
ROA (5Y Avg)-50.85%
Month-to-Date Return-7.67%
Cash Flow / Share (TTM)$-1.87
EBITD / Share (Annual)$-1.38
ROI (5Y Avg)-63.20%
EPS Basic Excl Extra (TTM)$-1.20
P/TBV (Quarterly)0.92x
P/B Ratio (Annual)3.43x
Book Value / Share (Annual)$1.42
Price vs S&P 500 (13W)-9.00%
Beta1.14x
Revenue / Share (TTM)$0.00
ROE (TTM)-101.19%
52-Week Low$1.85
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.23est. -0.29
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.19
4.19
4.19
4.19
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ANNXAnnexon, Inc. Common Stock | — | — | B | $5.58 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Annexon Inc is a clinical-stage biopharmaceutical company developing C1q inhibitors to treat complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. The company's platform technology targets the classical complement pathway across multiple disease areas affecting the body, brain, and eye. Its pipeline includes product candidates ANX005, ANX007, ANX009, and ANX1502 in development.